등온 핵산 증폭 기술 시장 : 제품 유형, 워크플로우, 기술, 최종 사용자, 용도별 예측(2026-2032년)

The Isothermal Nucleic Acid Amplification Technology Market is projected to grow by USD 13.77 billion at a CAGR of 13.09% by 2032.

Isothermal nucleic acid amplification technology is moving from a specialized molecular biology workflow to a frontline diagnostic platform for infectious disease testing, genetic testing, food safety, environmental surveillance, veterinary diagnostics, and decentralized molecular testing. Unlike PCR, isothermal amplification methods such as loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), nucleic acid sequence-based amplification (NASBA), helicase-dependent amplification (HDA), strand displacement amplification (SDA), and transcription-mediated amplification (TMA) amplify DNA or RNA at a constant temperature, reducing dependence on complex thermal cyclers.

The technology's market relevance is supported by measurable healthcare needs: the World Health Organization continues to identify tuberculosis, HIV, malaria, and respiratory infections as major global disease burdens, while post-pandemic health systems have increased investment in rapid molecular diagnostics, point-of-care testing, antimicrobial resistance monitoring, and syndromic surveillance. Isothermal nucleic acid amplification supports these priorities by enabling faster turnaround, simpler instrumentation, lower energy requirements, and potential deployment outside centralized laboratories.

Transformative Shifts in the Isothermal Amplification Landscape

The isothermal nucleic acid amplification landscape is being reshaped by decentralization, assay miniaturization, and integration with digital health systems. Laboratories and healthcare providers are shifting from batch-based, centralized molecular testing toward near-patient models that support faster clinical decisions in emergency departments, primary care, pharmacies, mobile clinics, border health programs, and field environments.

Another major shift is the convergence of isothermal amplification with CRISPR-based detection, microfluidics, lyophilized reagents, lateral-flow readouts, and sample-to-answer cartridges. These advances are improving analytical sensitivity, reducing contamination risk, and supporting multiplex testing. Regulatory expectations are also becoming more rigorous, with stronger emphasis on clinical validation, usability studies, manufacturing controls, cybersecurity, and data integrity for diagnostics used beyond traditional laboratory settings.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across the isothermal nucleic acid amplification ecosystem by improving assay design, signal interpretation, quality control, and operational decision-making. AI-enabled primer and probe design can reduce off-target amplification risk, while machine learning models can support faster optimization of reaction conditions for LAMP, RPA, NASBA, HDA, SDA, TMA, and related chemistries.

In connected diagnostic platforms, AI can enhance image-based fluorescence, turbidity, electrochemical, or colorimetric readouts, identify invalid reactions, and support epidemiological analytics when results are aggregated through secure digital systems. The most immediate impact is not the replacement of laboratory expertise, but the augmentation of assay development and decentralized testing workflows with better automation, predictive analytics, real-time quality monitoring, and standardized result interpretation.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for isothermal nucleic acid amplification, driven by large population bases, rising infectious disease surveillance, expanding domestic diagnostics manufacturing, and public health demand for rapid testing. China, India, Japan, South Korea, and Australia are supporting adoption through investments in molecular diagnostics, biotechnology infrastructure, public health laboratories, and point-of-care platforms, while regional priorities include tuberculosis, respiratory infections, dengue, antimicrobial resistance, food safety, and animal health surveillance.

North America remains a high-value region due to strong clinical laboratory networks, regulated diagnostic innovation, reimbursement focus on actionable testing, and sustained demand for respiratory, sexually transmitted infection, healthcare-associated infection, and antimicrobial resistance testing. Europe shows broad adoption through hospital laboratories, public health networks, academic translational research, and in vitro diagnostic regulation under the IVDR, while Latin America is advancing uptake in tuberculosis, dengue, Zika, chikungunya, agricultural diagnostics, and veterinary testing where access to centralized PCR infrastructure can be uneven.

The Middle East is investing in healthcare modernization, molecular laboratory capacity, population screening programs, and infectious disease preparedness, particularly across Gulf health systems. Africa represents a critical opportunity for robust, low-infrastructure nucleic acid amplification, with demand shaped by tuberculosis, HIV, malaria, Ebola and other viral hemorrhagic fever preparedness, maternal and child health needs, and decentralized testing requirements in rural and resource-limited settings.

Key Group Insights

ASEAN markets are increasingly relevant for isothermal nucleic acid amplification because of dense urban centers, tropical disease burden, cross-border mobility, and government interest in regional diagnostic self-reliance. Countries across Southeast Asia are using molecular tools for dengue, tuberculosis, respiratory infections, food safety, aquaculture, livestock disease, and animal health surveillance, creating demand for affordable, field-ready platforms that can perform reliably in varied temperature and infrastructure conditions.

The GCC is advancing adoption through high per-capita healthcare spending, national laboratory modernization, medical tourism, genomic medicine programs, and infectious disease preparedness initiatives. The European Union provides a highly structured regulatory environment where compliance with IVDR, clinical performance evidence, quality management systems, and post-market surveillance are central to market access. BRICS countries are important for scale, localization, public-sector procurement, and cost-sensitive manufacturing, while G7 markets influence global standards through advanced R&D, reimbursement frameworks, quality assurance expectations, and early adoption of next-generation diagnostics.

NATO countries are also relevant because biosecurity, outbreak readiness, military medicine, force health protection, and field-deployable diagnostics are strategic priorities. Across these groups, procurement decisions increasingly favor isothermal amplification platforms that combine validated performance, supply resilience, digital connectivity, interoperability with surveillance systems, cold-chain reduction, and usability in decentralized environments.

Key Country Insights

The United States leads in commercial innovation, FDA-cleared molecular diagnostics, venture-backed assay development, public health preparedness, and adoption across hospital, urgent care, pharmacy, and decentralized testing settings. Canada emphasizes public health surveillance, remote access, Indigenous and northern community healthcare needs, and quality-controlled diagnostic deployment, while Mexico and Brazil show growing demand for rapid molecular tools in infectious disease control, agricultural testing, veterinary health, and regional laboratory strengthening.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are advancing isothermal amplification through clinical diagnostics, academic research, hospital testing pathways, antimicrobial resistance initiatives, and regulated molecular testing adoption. Russia maintains demand for domestic molecular testing capacity and infectious disease monitoring, while Germany and France remain particularly important for technology validation, laboratory automation, quality systems, and regulated diagnostic adoption under European standards.

China is a major manufacturing and adoption hub, supported by scale, government-backed biotechnology growth, hospital infrastructure expansion, and broad infectious disease testing needs. India presents high potential due to tuberculosis, respiratory disease, antimicrobial resistance, maternal health needs, and decentralized healthcare requirements. Japan and South Korea contribute strong molecular diagnostics engineering, automation, microfluidics, and quality manufacturing capabilities, while Australia supports adoption through public health surveillance, veterinary diagnostics, biosecurity monitoring, and remote-area healthcare needs.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay robustness, simplified workflows, and clinically validated performance across sample types, environmental conditions, and user skill levels. The strongest opportunities are in sample-to-answer systems, multiplex respiratory and STI panels, antimicrobial resistance testing, tuberculosis detection, neglected tropical disease testing, food safety, environmental monitoring, and veterinary applications where speed and field deployment create measurable value.

Organizations should invest in lyophilized reagents, contamination control, closed-cartridge systems, internal controls, digital result capture, interoperability, and AI-assisted interpretation while building regulatory strategies early. Partnerships with public health agencies, regional manufacturers, reference laboratories, procurement bodies, and distribution networks can improve access and supply resilience. Commercial success will depend on proving not only analytical sensitivity and specificity, but also workflow efficiency, total cost of ownership, implementation feasibility, user training requirements, and clinical or public health impact.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with rigorous market intelligence practices. The analysis synthesizes publicly available information from regulatory agencies, public health authorities, peer-reviewed literature, clinical guideline sources, product documentation, patent and technology trend reviews, procurement signals, and scientific publications related to isothermal nucleic acid amplification technology.

Market interpretation is based on triangulation across disease burden, regulatory movement, technology readiness, laboratory infrastructure, public health priorities, reimbursement considerations, decentralized testing adoption, and observed trends in molecular diagnostics. Claims are framed conservatively and focus on verifiable trends, established technology capabilities, documented use cases, and observable demand drivers rather than speculative projections, market sizing, or market share estimates.

Conclusion

Isothermal nucleic acid amplification technology is becoming an essential pillar of rapid molecular diagnostics because it aligns with the global need for accessible, fast, and reliable nucleic acid testing. Its ability to operate without thermal cycling makes it well suited for decentralized healthcare, outbreak response, resource-limited environments, veterinary and food safety workflows, and high-throughput laboratory use cases where simplified instrumentation can improve operational efficiency.

The next phase of industry development will be defined by validated multiplexing, AI-supported assay development, CRISPR-enabled detection, connected point-of-care platforms, lyophilized reagent stability, and resilient manufacturing. Organizations that combine scientific rigor with usability, regulatory readiness, digital connectivity, and region-specific access strategies will be best positioned to lead adoption in clinical, public health, environmental, and industrial testing applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Isothermal Nucleic Acid Amplification Technology Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Benchtop
  • 7.1.2. Portable
• 7.2. Reagents & Kits
  • 7.2.1. Control Materials
  • 7.2.2. Enzymes
  • 7.2.3. Master Mixes
  • 7.2.4. Primers & Probes
• 7.3. Software & Services
  • 7.3.1. Services
  • 7.3.2. Software

8. Isothermal Nucleic Acid Amplification Technology Market, by Workflow

• 8.1. Amplification
• 8.2. Detection & Analysis
  • 8.2.1. End-Point Detection
  • 8.2.2. Real-Time Detection
• 8.3. Preanalytical

9. Isothermal Nucleic Acid Amplification Technology Market, by Technology

• 9.1. Helicase Dependent Amplification
• 9.2. Loop Mediated Isothermal Amplification
  • 9.2.1. Colorimetric Detection
  • 9.2.2. Fluorescence Detection
  • 9.2.3. Turbidimetric Detection
• 9.3. Nicking Enzyme Amplification Reaction
• 9.4. Recombinase Polymerase Amplification
  • 9.4.1. Fluorescence Detection
  • 9.4.2. Lateral Flow Detection
  • 9.4.3. Real Time Detection
• 9.5. Strand Displacement Amplification

10. Isothermal Nucleic Acid Amplification Technology Market, by End User

• 10.1. Academic & Research Institutes
• 10.2. Hospitals & Diagnostic Laboratories
• 10.3. Pharmaceutical & Biotechnology Companies
• 10.4. Point Of Care Centers

11. Isothermal Nucleic Acid Amplification Technology Market, by Application

• 11.1. Environmental Testing
• 11.2. Food & Beverage Testing
• 11.3. Genetic Testing & Screening
• 11.4. Infectious Disease Diagnostics
• 11.5. Veterinary Diagnostics

12. Isothermal Nucleic Acid Amplification Technology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Isothermal Nucleic Acid Amplification Technology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Isothermal Nucleic Acid Amplification Technology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AtilaBiosystems
• 16.3. Beijing SBS Genetech Co., Ltd.
• 16.4. bioMerieux SA
• 16.5. Biosearch Technologies by LGC Limited
• 16.6. DiaSorin S.p.A.
• 16.7. Eiken Chemical Co., Ltd.
• 16.8. Fortis Life Sciences, LLC
• 16.9. GENOMTEC S.A.
• 16.10. GenoSensor Corporation
• 16.11. Grifols, S.A.
• 16.12. highQu GmbH
• 16.13. Hologic, Inc.
• 16.14. Illumina, Inc.
• 16.15. Jena Bioscience GmbH
• 16.16. Life Sciences Advanced Technologies, Inc.
• 16.17. Mast Group Ltd.
• 16.18. Meridian Bioscience Inc. by SD Biosensor, Inc.
• 16.19. New England Biolabs, Inc.
• 16.20. OptiGene Limited
• 16.21. PCR Biosystems Ltd.
• 16.22. QIAGEN GmbH
• 16.23. Quidel Corporation
• 16.24. Tecan Trading AG
• 16.25. Thermo Fisher Scientific Inc.
• 16.26. Ustar Biotechnologies (Hangzhou) Ltd
• 16.27. Xiamen Jiqing Biomedical Technology Co., Ltd.
• 16.28. Zhengzhou Laboao Instrument Equipment CO., LTD
• 16.29. Zhuhai Biori Biotechnology Co., Ltd.